Keryx Biopharmaceuticals (NASDAQ:KERX)’s share price hit a new 52-week low during trading on Tuesday . The stock traded as low as $2.74 and last traded at $2.83, with a volume of 34948 shares changing hands. The stock had previously closed at $2.90.
A number of research firms recently commented on KERX. Zacks Investment Research upgraded Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 9th. HC Wainwright set a $9.00 target price on Keryx Biopharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, October 2nd. BidaskClub upgraded Keryx Biopharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, September 21st. Finally, Citigroup decreased their target price on Keryx Biopharmaceuticals from $4.75 to $4.00 and set a “neutral” rating on the stock in a research report on Thursday, August 9th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the stock. Keryx Biopharmaceuticals presently has an average rating of “Hold” and an average target price of $6.25.
The stock has a market capitalization of $353.90 million, a P/E ratio of -3.19 and a beta of 2.46.
Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). The company had revenue of $25.75 million during the quarter. As a group, research analysts expect that Keryx Biopharmaceuticals will post -0.61 earnings per share for the current fiscal year.
Several large investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. purchased a new stake in Keryx Biopharmaceuticals during the first quarter valued at approximately $201,000. UBS Group AG raised its position in Keryx Biopharmaceuticals by 126.0% during the first quarter. UBS Group AG now owns 231,934 shares of the biopharmaceutical company’s stock valued at $949,000 after purchasing an additional 129,296 shares during the period. Millennium Management LLC purchased a new stake in Keryx Biopharmaceuticals during the first quarter valued at approximately $3,847,000. Shufro Rose & Co. LLC raised its position in Keryx Biopharmaceuticals by 26.1% during the second quarter. Shufro Rose & Co. LLC now owns 91,800 shares of the biopharmaceutical company’s stock valued at $345,000 after purchasing an additional 19,000 shares during the period. Finally, Rice Hall James & Associates LLC raised its position in Keryx Biopharmaceuticals by 18.9% during the second quarter. Rice Hall James & Associates LLC now owns 2,278,007 shares of the biopharmaceutical company’s stock valued at $8,565,000 after purchasing an additional 361,533 shares during the period. Institutional investors own 59.41% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece of content was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/11/06/keryx-biopharmaceuticals-kerx-sets-new-12-month-low-at-2-74.html.
About Keryx Biopharmaceuticals (NASDAQ:KERX)
Keryx Biopharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis.
Read More: Earnings Per Share (EPS) Explained
Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.